Name in SEC filings: ROCKET PHARMACEUTICALS, INC.
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| KRESLADI / RP-L201 | submission | — | in 2025 | 10-Q · |
| marnetegragene autotemcel (KRESLADI) | target date (company stated) | PDUFA | March 28, 2026 | SEC filing · |
Source: ORION, orionbiotechai.com/company/RCKT, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/RCKT
marnetegragene autotemcel (KRESLADI) · PDUFA target date (company stated) · March 28, 2026 · SEC filing filed
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
severe leukocyte adhesion deficiency-I
NDA/BLA submissionin 2025
Stage: —
Public float: $212,500,000 · as of · SEC filing
Submission of a complete BLA to resolve CRL is anticipated in 2025.
10-Q · Filed · Last checked
Resolution filing: · SEC filing
Alert me · Calendar: same stage and window-end month (2025-12)
severe leukocyte adhesion deficiency-I
PDUFA target date (company stated)March 28, 2026
Stage: PDUFASEC filing · “PDUFA) target action date”
Public float: $212,500,000 · as of · SEC filing
Prescription Drug User Fee Act (PDUFA) target action date for March 28, 2026
SEC filing · Filed · Last checked
Resolution filing: · SEC filing
Alert me · Calendar: same stage and window-end month (2026-03)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| marnetegragene autotemcel (KRESLADI)FDA decision | March 28, 2026“Prescription Drug User Fee Act (PDUFA) target action date for March 28, 2026” Filed · SEC original | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| marnetegragene autotemcel (KRESLADI)FDA decision | March 28, 2026“PDUFA date of March 28, 2026” Filed · SEC original | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| marnetegragene autotemcel (KRESLADI)FDA decision | March 28, 2026“PDUFA date of March 28, 2026” Filed · SEC original | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| marnetegragene autotemcel (KRESLADI)FDA decision | March 28, 2026“PDUFA date set by the FDA is March 28, 2026” Filed · SEC original | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| marnetegragene autotemcel (KRESLADI)FDA decision | March 28, 2026“PDUFA date set by the FDA is March 28, 2026” Filed · SEC original | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| KRESLADI / RP-L201Submission | in 2025“Submission of a complete BLA to resolve CRL is anticipated in 2025.” Filed · 10-Q | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| KRESLADI / RP-L201Submission | before the end of 2025“submission of complete BLA to resolve Complete Response Letter is anticipated before the end of 2025.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| KRESLADI / RP-L201Submission | in 2025“Submission of complete BLA to resolve Complete Response Letter anticipated in 2025.” Filed · EX-99.1 | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| KRESLADI / RP-L201Submission | in 2025“Submission of a complete BLA to resolve the CRL is anticipated in 2025.” Filed · 10-Q | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| KRESLADI / RP-L201Submission | in 2025“Submission of a complete BLA to resolve CRL is anticipated in 2025.” Filed · 10-Q | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| KRESLADI / RP-L201Submission | in 2025“Submission of complete BLA to resolve Complete Response Letter anticipated in 2025.” Filed · EX-99.1 | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| KRESLADI / RP-L201Submission | in 2025“Submission of complete BLA to resolve Complete Response Letter anticipated in 2025.” Filed · 10-K | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.
Historical catalog checked .
No historical announcement trail is retained for this company in this catalog.
Original ClinicalTrials.gov record · Open the selected study
These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.
Coverage and identity checksSuggest an SEC timing statement to add for RCKT. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See RCKT in the calendar · Review labels and methodology